DV Medical Supply, Inc.

2000 W 135th Street
Gardena, CA. 90249
US

800-438-2568

Lovastatin Tabs 10mg #100
Lovastatin Tabs 10mg #100

Lovastatin Tabs 10mg #100

Out of Stock
Part Number:DVM-101288
MPN:
Manufacturer: Carlsbad Technology

NDC:

61442-0141-01
You need to have an approved DV Med account to order this product.

Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other non-pharmacological measures alone has been inadequate to reduce risk.

Primary Prevention of Coronary Heart Disease
In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of:

Myocardial infarction
Unstable angina
Coronary revascularization procedures

Coronary Heart Disease
Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels.

Hypercholesterolemia
Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate.

Adolescent Patients with Heterozygous Familial Hypercholesterolemia
Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present:
  1. LDL-C remains >189 mg/dL or
  2. LDL-C remains >160 mg/dL and:
    • there is a positive family history of premature cardiovascular disease or
    • two or more other CVD risk factors are present in the adolescent patient

Related Items